Pozo-Rosich P - Search Results

1

Safety and efficacy of galcanezumab in patients for whom previous migraine preventive medication from two to four categories had failed (CONQUER): a multicentre, randomised, double-blind, placebo-controlled, phase 3b trial.

Mulleners WM, Kim BK, Láinez MJA, Lanteri-Minet M, Pozo-Rosich P, Wang S, Tockhorn-Heidenreich A, Aurora SK, Nichols RM, Yunes-Medina L, Detke HC. Mulleners WM, et al. Lancet Neurol. 2020 Oct;19(10):814-825. doi: 10.1016/S1474-4422(20)30279-9. Epub 2020 Sep 16. Lancet Neurol. 2020. PMID: 32949542 Clinical Trial.

2

[Importance of diagnosis and treatment in chronic migraine].

Pozo-Rosich P. Pozo-Rosich P. Rev Neurol. 2014 Mar 10;58 Suppl 2:S1. Rev Neurol. 2014. PMID: 24687879 Free article. Spanish.

3

[What benefits does the preventive treatment of migraine have?].

Pozo-Rosich P. Pozo-Rosich P. Rev Neurol. 2014 Mar 10;58 Suppl 2:S21-6. Rev Neurol. 2014. PMID: 24687881 Free article. Spanish.

4

Comorbidity between idiopathic overactive bladder and chronic migraine.

Ramos ML, García-Cabo C, Leira R, Domínguez C, Pozo-Rosich P, Vila C, Laínez MJ, Pascual J. Ramos ML, et al. Cephalalgia. 2018 Mar;38(3):581-584. doi: 10.1177/0333102417690127. Epub 2017 Jan 23. Cephalalgia. 2018. PMID: 28114808

5

The impact of onabotulinumtoxinA on severe headache days: PREEMPT 56-week pooled analysis.

Matharu M, Halker R, Pozo-Rosich P, DeGryse R, Manack Adams A, Aurora SK. Matharu M, et al. J Headache Pain. 2017 Dec;18(1):78. doi: 10.1186/s10194-017-0784-4. Epub 2017 Aug 1. J Headache Pain. 2017. PMID: 28766236 Free PMC article. Clinical Trial.

6

OnabotulinumtoxinA in chronic migraine: predictors of response. A prospective multicentre descriptive study.

Domínguez C, Pozo-Rosich P, Torres-Ferrús M, Hernández-Beltrán N, Jurado-Cobo C, González-Oria C, Santos S, Monzón MJ, Latorre G, Álvaro LC, Gago A, Gallego M, Medrano V, Huerta M, García-Alhama J, Belvís R, Leira Y, Leira R. Domínguez C, et al. Eur J Neurol. 2018 Feb;25(2):411-416. doi: 10.1111/ene.13523. Epub 2017 Dec 18. Eur J Neurol. 2018. PMID: 29171146

7

Guidelines of the International Headache Society for controlled trials of preventive treatment of chronic migraine in adults.

Tassorelli C, Diener HC, Dodick DW, Silberstein SD, Lipton RB, Ashina M, Becker WJ, Ferrari MD, Goadsby PJ, Pozo-Rosich P, Wang SJ; International Headache Society Clinical Trials Standing Committee. Tassorelli C, et al. Cephalalgia. 2018 Apr;38(5):815-832. doi: 10.1177/0333102418758283. Epub 2018 Mar 4. Cephalalgia. 2018. PMID: 29504482

8

OnabotulinumtoxinA: An Effective Tool in the Therapeutic Arsenal for Chronic Migraine With Medication Overuse.

Caronna E, Gallardo VJ, Hernández-Beltrán N, Torres-Ferrus M, Pozo-Rosich P. Caronna E, et al. Front Neurol. 2018 Oct 16;9:808. doi: 10.3389/fneur.2018.00808. eCollection 2018. Front Neurol. 2018. PMID: 30386285 Free PMC article.

9

How much do calcitonin gene-related peptide monoclonal antibodies improve the quality of life in migraine? A patient's perspective.

Torres-Ferrus M, Alpuente A, Pozo-Rosich P. Torres-Ferrus M, et al. Curr Opin Neurol. 2019 Jun;32(3):395-404. doi: 10.1097/WCO.0000000000000689. Curr Opin Neurol. 2019. PMID: 30950844 Review.

10

Early efficacy and late gain in chronic and high-frequency episodic migraine with onabotulinumtoxinA.

Alpuente A, Gallardo VJ, Torres-Ferrus M, Alvarez-Sabin J, Pozo-Rosich P. Alpuente A, et al. Eur J Neurol. 2019 Dec;26(12):1464-1470. doi: 10.1111/ene.14028. Epub 2019 Jul 18. Eur J Neurol. 2019. PMID: 31220392

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

199 results

Search Page